CEACAM5 and carcinoma: Applying the afore described test algorithm to 80 early stage carcinomas of the combined training and validation set, the sensitivity was 33% (95%CI: 22-44%) for the combination of CEA + IL-8 and 28% (95%CI: 18-39%) for the combination of CEA + CRP, each at a specificity of 86% (95%CI: 73-94%).